FDA Permits Marketing of App to Help Treat Substance Abuse

Share this content:
FDA Permits Marketing of App to Help Treat Substance Abuse
FDA Permits Marketing of App to Help Treat Substance Abuse

THURSDAY, Sept. 14, 2017 (HealthDay News) -- The U.S. Food and Drug Administration has permitted marketing of the first mobile app to help treat substance use disorders, the agency said Thursday in a news release.

The Reset application is designed to help treat abuse of alcohol, cocaine, marijuana, and stimulant medications. But the app is not intended for opioid dependence, the FDA said.

The newly-approved app delivers behavioral therapy that's designed to "increase abstinence from substance abuse and increase retention in outpatient therapy programs," the FDA said.

The agency reviewed a 12-week clinical study involving 399 patients. Among those who used the app, 40.3 percent abstained from further alcohol, cocaine, marijuana, or stimulant use, compared with 17.6 percent among those who did not use the app.

Approval of the app was given to Pear Therapeutics, based in Boston and San Francisco.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Lyme-Bearing Ticks More Widespread in U.S. Than Thought

Lyme-Bearing Ticks More Widespread in U.S. Than Thought

Disease-carrying ticks were detected in 83 counties where they'd never been found before

Availability of Generic Antivirals for Hepatitis B Increasing

Availability of Generic Antivirals for Hepatitis B Increasing

Drop in median price of WHO-prequalified generic tenofovir from $208 to $32 from 2004 to 2016

Visual Function Deficits Up in Developmental Dyslexia

Visual Function Deficits Up in Developmental Dyslexia

Increased prevalence of deficits in visual function versus typically developing school-age children

is free, fast, and customized just for you!




Already a member?

Sign In Now »